Table J.

Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (telaprevir provided at a dose of 750 mg three times per day during weeks 1–12 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks) among patients with compensated cirrhosis

Trial	Intervention		Control		Relative risk (95% CI)
	N	Pooled (95% CI)	N	Pooled (95% CI)
Sustained virologic response
Naïve patients
Jacobson et al8	13/21	61% (47%–75%)	7/21	34% (21%–49%)	1.86 (1.14–3.03)
Experienced patients
Zeuzem et al14	77/119	65% (58%–71%)	6/59	11% (6%–17%)	6.36 (3.69–10.97)

Abbreviation: CI, confidence interval.